Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. At Harvard's Edmond J.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Marshall Goldsmith

FEBRUARY 8, 2018

Lead author of Business Model Generation and Value Proposition Design , which sold over one million copies in 37 languages. Deepa Prahalad – Focused on design and emerging markets. Advisor and Speaker at Dartmouth’s Tuck School of Business. Telisa Yancy – Chief Marketing Officer at American Family Insurance.

Executive Coaching 70

Executive Coaching CEO Magazine Banking 70

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. Experimentation is vital.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. One antidote to these problems is to transform “access to medicine” from a relentless activist slogan to a fully-fledged business strategy. citizens than pharmaceuticals (the sector’s worst showing in 16 years).

Reputation 8

Reputation Pharmaceuticals Price Business Model 8